Voriconazole pharmacokinetics and photosensitivity in children with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 11, Issue 3, 2012, Pages 246-252

  Markantonis, Sophia L ^a   Katelari, Anna ^b   Pappa, Eleni ^a   Doudounakis, Stavros ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Allergic bronchopulmonary aspergillosis; Cystic fibrosis; Pharmacokinetics; Photosensitivity; Voriconazole

Indexed keywords

VORICONAZOLE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHEILITIS; CHILD; CLINICAL ARTICLE; CORRELATION ANALYSIS; CYSTIC FIBROSIS; DERMATITIS; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GREECE; HEADACHE; HUMAN; LONG TERM CARE; MALE; PHOTOPHOBIA; PHOTOSENSITIVITY; RISK FACTOR; SCHOOL CHILD; SIDE EFFECT; SUN EXPOSURE; TREMOR; VISUAL DISORDER;

ADMINISTRATION, ORAL; ADOLESCENT; ANTIFUNGAL AGENTS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; CHILD; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROSPECTIVE STUDIES; PYRIMIDINES; SUNLIGHT; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 84860642574     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2011.12.006     Document Type: Article

References (28)

1. Müller F.M., Seidler M. Characteristics of pathogenic fungi and antifungal therapy in cystic fibrosis. Expert Rev Anti Infect Ther 2010, 8(8):957-964.
2. Prasad P.A., Coffin S.E., Leckerman K.H., Walsh T.J., Zaoutis T.E. Pediatric antifungal utilization: new drugs, new trends. Pediatr Infect Dis J 2008, 27:1083-1088.
3. Walsh T.J., Karlsson M.O., Driscoll T., Arguedas AG, Adamson P, Saez-LLorens X, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004, 48:2166-2172.
4. Karlsson M.O., Lutsar I., Milligan P.A. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009, 53(3):935-944.
5. Hilliard T., Edwards S., Buchdahl R., Francis J., Rosenthal M, Balfour-Lynn I, et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros 2005, 4:215-220.
6. Glackin L., Leen G., Elnazir B., Greally P. Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Ir Med J 2009, 102(1):29.
7. Neely M., Rushing T., Kovacs A., Jelliffe R., Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010, 50:27-36.
8. Tan K., Brayshaw N., Tomaszewski K., Troke P., Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006, 46(2):235-243.
9. Lutsar I., Hodges M.R., Tomaszeewski K., Troke P.F., Wood N.D. Safety of voriconazole and dose individualization. Clin Infect Dis 2003, 36:1087-1088.
10. Malani A.N., Aronoff D.M. Voriconazole-induced photosensitivity. Clin Med Res 2008, 6(2):83-85.
11. McCarthy K.L., Playford E.G., Looke D.F., Whitby M.Q. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 2007, 44(5):e55-e56.
12. Cowen E.W., Nguyen J.C., Miller D.D., McShane D, Arron ST, Prose NS, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010, 62(1):31-37.
13. Vöhringer S., Schrum J., Ott H., Höger P.H. Severe phototoxicity associated with long-term voriconazole treatment. J Dtsch Dermatol Ges 2011, 9(4):274-276.
14. FDA Antiviral Drugs Advisory Committee. Briefing Document for Voriconazole (Oral and Intravenous formulations), 2001. []. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01_Pfizer.pdf.
15. Stevens D.A., Moss R.B., Kurup V.P., Knutsen AP, Greenberger P, Judson MA, et al. Participants in the Cystic Fibrosis Foundation Concensus Conference. Clin Infect Dis 2003, 37(Suppl. 3):S225-S264.
16. Lippert H., Lehmann H.P. SI units in Medicine: an introduction to the international system of units with conversion tables and normal ranges 1978, Urban & Schwarzenberg, Baltimore-Munich, USA. First ed.
17. Gage R., Stopher D.A. A rapid HPLC assay for voriconazole in human plasma. J Pharm Biomed Anal 1998, 17:1449-1453.
18. Denning D.W., Griffiths C.E. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 2001, 26:648-653.
19. Cheng M.P., Paquette K., Lands L.C., Ovetchkine P., Theoret Y., Quach C. Voriconazole inhibition of vitamin A metabolism: are adverse events increased in cystic fibrosis patients?. Pediatr Pulmonal 2010, 45:661-666.
20. Johnson L.B., Kauffman C.A. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003, 36:630-637.
21. Racette A.J., Roenigk H.H., Hansen R., Mendelson D., Park A. Photoaging and phototoxicity from long-term voriconazole treatment in a 15-year-old girl. J Am Acad Dermatol 2005, 52(5 Suppl 1):S81-S85.
22. Pascual A., Calandra T., Bolay S., Buclin T., Bille J., Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008, 46(2):201-211.
23. Prandote J. Clinical pharmacology of antibiotics and other drugs in cystic fibrosis. Drugs 1988, 35(5):542-578.
24. Berge M., Guillemain R., Tregouet D.A., Amrein C, Boussaud V, Chevalier P, et al. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. Eur J Clin Pharmacol 2011, 67(3):253-260.
25. Azanza J.R., Garcia-Quetglas E., Sadaba B. Pharmacology of azoles. Rev Ineroam Micol 2007, 24:223-227.
26. Katelari A., Lympari J., Kapi A., Xenofonte K., Doudounakis S. Voriconazole therapy in children with cystic fibrosis and steroid-dependent allergic bronchopulmonary aspergillosis: efficacy and adverse effects. 32nd European Cystic Fibrosis Conference 2009.
27. Capitano B., Potoski B.A., Husain S., Zhang S, Paterson DL, Studer SM, et al. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob Agents Chemother 2006, 50(5):1878-1880.
28. Wang G., Lei H.P., Li Z., Tan ZR, Guo D, Fan L, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 2009, 65:281-285.